Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan 13;90(1):110-8.
doi: 10.1016/j.ajhg.2011.11.018. Epub 2011 Dec 15.

Mutations in EZH2 cause Weaver syndrome

Affiliations

Mutations in EZH2 cause Weaver syndrome

William T Gibson et al. Am J Hum Genet. .

Abstract

We used trio-based whole-exome sequencing to analyze two families affected by Weaver syndrome, including one of the original families reported in 1974. Filtering of rare variants in the affected probands against the parental variants identified two different de novo mutations in the enhancer of zeste homolog 2 (EZH2). Sanger sequencing of EZH2 in a third classically-affected proband identified a third de novo mutation in this gene. These data show that mutations in EZH2 cause Weaver syndrome.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Proband from Weaver et al. and Two Additional Probands Described in This Study Proband 1 is shown at 18 months (A), 6 years (B), 11 years (C), 17 years (D), 21 years (E), and 30 years (F, G, and H). Proband 2 is shown at age 7 years (I) and 13 years (J, K, and L). Proband 3 is shown at birth (M), 12 months (N), 24 months (O), 42 months (P), 6 years (Q), 10 years (R), 11 years (S), 16 years (T), and 19 years (U and V). Proband 3 at 8 years in a stance that shows elbow and knee contractures (W). Photos are published with the proxy consent of the parents and assent of the probands.
Figure 2
Figure 2
Sanger Confirmation of Sequence Variants (A) The c.457_459del mutation in Proband 1 (curly bracket) is de novo. (B) The c.2080C>T mutation in Proband 2 (arrow) is de novo. (C) The c.394C>T mutation in Proband 3 (arrow) is de novo.
Figure 3
Figure 3
Schematic of Human EZH2 Coding exons are indicated by rectangles and noncoding exons by open rectangles. The exons are numbered starting from the exon containing the 5′ untranslated region (UTR). The putative SANT DNA-binding domain is shown in orange, the SET domain in blue, and the WD-binding domain in green. The SMART or Pfam domain identifier is presented in parentheses. Exons with no InterPro annotation are indicated in gray.
Figure 4
Figure 4
Ribbon Model of the EZH2 SET Domain The wild-type histidine residue is shown in blue and the bulkier tyrosine in white and red. The nearby binding site of the S-Adenosylmethionine cofactor is also indicated.

Similar articles

  • Mutations in genes encoding polycomb repressive complex 2 subunits cause Weaver syndrome.
    Imagawa E, Higashimoto K, Sakai Y, Numakura C, Okamoto N, Matsunaga S, Ryo A, Sato Y, Sanefuji M, Ihara K, Takada Y, Nishimura G, Saitsu H, Mizuguchi T, Miyatake S, Nakashima M, Miyake N, Soejima H, Matsumoto N. Imagawa E, et al. Hum Mutat. 2017 Jun;38(6):637-648. doi: 10.1002/humu.23200. Epub 2017 Mar 15. Hum Mutat. 2017. PMID: 28229514
  • Germline mutations in the oncogene EZH2 cause Weaver syndrome and increased human height.
    Tatton-Brown K, Hanks S, Ruark E, Zachariou A, Duarte Sdel V, Ramsay E, Snape K, Murray A, Perdeaux ER, Seal S, Loveday C, Banka S, Clericuzio C, Flinter F, Magee A, McConnell V, Patton M, Raith W, Rankin J, Splitt M, Strenger V, Taylor C, Wheeler P, Temple KI, Cole T; Childhood Overgrowth Collaboration; Douglas J, Rahman N. Tatton-Brown K, et al. Oncotarget. 2011 Dec;2(12):1127-33. doi: 10.18632/oncotarget.385. Oncotarget. 2011. PMID: 22190405 Free PMC article.
  • Weaver syndrome and EZH2 mutations: Clarifying the clinical phenotype.
    Tatton-Brown K, Murray A, Hanks S, Douglas J, Armstrong R, Banka S, Bird LM, Clericuzio CL, Cormier-Daire V, Cushing T, Flinter F, Jacquemont ML, Joss S, Kinning E, Lynch SA, Magee A, McConnell V, Medeira A, Ozono K, Patton M, Rankin J, Shears D, Simon M, Splitt M, Strenger V, Stuurman K, Taylor C, Titheradge H, Van Maldergem L, Temple IK, Cole T, Seal S; Childhood Overgrowth Consortium; Rahman N. Tatton-Brown K, et al. Am J Med Genet A. 2013 Dec;161A(12):2972-80. doi: 10.1002/ajmg.a.36229. Epub 2013 Nov 8. Am J Med Genet A. 2013. PMID: 24214728
  • Novel de novo mutation affecting two adjacent aminoacids in the EED gene in a patient with Weaver syndrome.
    Smigiel R, Biernacka A, Biela M, Murcia-Pienkowski V, Szmida E, Gasperowicz P, Kosinska J, Kostrzewa G, Koppolu AA, Walczak A, Wawrzuta D, Rydzanicz M, Sasiadek M, Ploski R. Smigiel R, et al. J Hum Genet. 2018 Apr;63(4):517-520. doi: 10.1038/s10038-017-0391-x. Epub 2018 Feb 6. J Hum Genet. 2018. PMID: 29410511 Review.
  • Overgrowth syndromes.
    Neylon OM, Werther GA, Sabin MA. Neylon OM, et al. Curr Opin Pediatr. 2012 Aug;24(4):505-11. doi: 10.1097/MOP.0b013e3283558995. Curr Opin Pediatr. 2012. PMID: 22705997 Review.

Cited by

References

    1. Weaver D.D., Graham C.B., Thomas I.T., Smith D.W. A new overgrowth syndrome with accelerated skeletal maturation, unusual facies, and camptodactyly. J. Pediatr. 1974;84:547–552. - PubMed
    1. Fryer A., Smith C., Rosenbloom L., Cole T. Autosomal dominant inheritance of Weaver syndrome. J. Med. Genet. 1997;34:418–419. - PMC - PubMed
    1. Proud V.K., Braddock S.R., Cook L., Weaver D.D. Weaver syndrome: Autosomal dominant inheritance of the disorder. Am. J. Med. Genet. 1998;79:305–310. - PubMed
    1. Douglas J., Hanks S., Temple I.K., Davies S., Murray A., Upadhyaya M., Tomkins S., Hughes H.E., Cole T.R., Rahman N. NSD1 mutations are the major cause of Sotos syndrome and occur in some cases of Weaver syndrome but are rare in other overgrowth phenotypes. Am. J. Hum. Genet. 2003;72:132–143. - PMC - PubMed
    1. Rio M., Clech L., Amiel J., Faivre L., Lyonnet S., Le Merrer M., Odent S., Lacombe D., Edery P., Brauner R., et al. Spectrum of NSD1 mutations in Sotos and Weaver syndromes. J. Med. Genet. 2003;40:436–440. - PMC - PubMed

Publication types

MeSH terms

Substances

Supplementary concepts